

GelTex Pharmaceuticals Incorporated

[View the current GelTex Pharmaceuticals Incorporated Page on BioPortfolio.com](http://www.bioportfolio.com/bioporporate/4323-GelTex+Pharmaceuticals+Incorporated.html)

(<http://www.bioportfolio.com/bioporporate/4323-GelTex+Pharmaceuticals+Incorporated.html>)

Contact Details:

9 Fourth Avenue

Waltham

MA

02451

United States of America

Tel: 781 290 5888

Fax: 617 290 5890

Email:

GelTex Pharmaceuticals, Inc. is developing non-absorbed, polymer-based pharmaceuticals that selectively bind to and eliminate target substances from the intestinal tract. In October 1998, the Company received approval from the United States Food and Drug Administration (the "FDA") for its lead product Renagel(R)* Capsules (sevelamer hydrochloride).

Additionally, throughout 1998, the Company continued its product development efforts focused on therapeutic agents for the treatment of hypercholesterolemia (elevated LDL cholesterol levels); obesity; and infectious diseases.

Recent Publications by GelTex Pharmaceuticals Incorporated:



- [Bile acid binding to sevelamer HCl.](#)

*BACKGROUND: Clinical studies have shown sevelamer HCl (Renagel) to be...*14th January, 2003
GelTex Pharmaceuticals, Waltham, Massachusetts, USA.- *Kidney Int.* 2002 Aug;62(2):611-9. ([DOI Direct Link](#))

- [A phosphate binding assay for sevelamer hydrochloride by ion chromatography.](#)

*Sevelamer hydrochloride is a cross-linked polymeric amine; it is the...*25th March, 2000
GelTex Pharmaceuticals, Waltham, MA 02154, USA. www.geltex.com.- *J Pharm Biomed Anal.* 1999 May;19(6):911-5.

Press Releases on GelTex Pharmaceuticals Incorporated:

"As an Industry, We've Been too Focused on Regulatory Approval." Says Solvay Pharmaceuticals Eric Rambeaux at the Pharma Marketing Summit.	26th November, 2009		LONDON, November 26 /PRNewswire/ -- Rambeaux joined a host of other industry leaders at eyeforpharma's 9th annual Pharma Marketing Summit 2009 conference in Berlin, where several key themes
Onyx Pharmaceuticals Announces December 2009 Investor Events	25th November, 2009	Onyx Pharmaceuticals, Inc.	EMERYVILLE, Calif., Nov. 25 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that the company will host two investor events in December: ASH Briefing December 7, SAN DIEGO, Nov. 25 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) announced today that Barry D. Quart, Pharm.D., president and chief executive officer, will present at the Piper DELFT, The Netherlands and JOHANNESBURG, November 25 /PRNewswire/ -- iThemba Pharmaceuticals's service division and Pyxis Discovery announced today that they have signed a collaborative agreement
Ardea Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference	25th November, 2009	Ardea Biosciences, Inc.	
iThemba Pharmaceuticals (Pty) Ltd and Pyxis Discovery B.V. Announce Collaborative Agreement to Offer a Combined Service Offering	25th November, 2009		NEW YORK, Nov. 25 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Cell/Tissue Culture Supplies - A Global Market Perspective http://www
Reportlinker Adds Cell/Tissue Culture Supplies - A Global Market Perspective	25th November, 2009	Reportlinker	

BioNews Results for GelTex Pharmaceuticals Incorporated



- [NUCRYST Announces Special Meeting of Shareholders](#)
KLFY: Nov 22 2009 12:21AM Matching: pharmaceuticals
- [Alnylam Pharmaceuticals Down 21.5% Since SmarTrend's Sell Recommendation](#)

- TradingMarkets: Nov 21 2009 7:26PM Matching: pharmaceuticals*
- [NUCRYST Announces Special Meeting of Shareholders](#)
TickerTech.com: Nov 21 2009 8:43PM Matching: pharmaceuticals
- [NUCRYST Announces Special Meeting of Shareholders](#)
KSLA: Nov 21 2009 7:19PM Matching: pharmaceuticals
- [NUCRYST Announces Special Meeting of Shareholders](#)
Montana's News Station: Nov 21 2009 12:32PM Matching: pharmaceuticals
- [Webcast Alert: Isis Pharmaceuticals Announces Its R&D Webcast Presentation](#)
MedIndia: Nov 20 2009 4:45AM Matching: pharmaceuticals
- [Minster Pharma. PLC : Interim Results](#)
Investegate: Nov 20 2009 7:44AM Matching: pharmaceuticals
- [NYSSA Presents 13th Annual Biotech and Specialty Pharmaceuticals Conference](#)
Reuters: Nov 20 2009 8:58PM Matching: pharmaceuticals
- [Company Profile for Amneal Pharmaceuticals, LLC](#)
Reuters: Nov 20 2009 4:21PM Matching: pharmaceuticals
- [Endo Pharmaceuticals \(ENDP\) Trading On Heavy Volume - Zibb.com](#)
Zibb: Nov 20 2009 3:36PM Matching: pharmaceuticals
- [Endo Pharmaceuticals \(ENDP\) Trading On Heavy Volume - Zibb.com](#)
Zibb: Nov 20 2009 3:36PM Matching: pharmaceuticals
- [Endo Pharmaceuticals and LecTec Settle Patent Dispute](#)
Pharma Live: Nov 20 2009 3:36PM Matching: pharmaceuticals
- [Webcast Alert: Isis Pharmaceuticals Announces Its R&D Webcast Presentation](#)
SmartBrief: Nov 20 2009 6:49AM Matching: pharmaceuticals
- [Alexza Pharmaceuticals to Present at the 21st Annual Piper Jaffra...](#)
Zibb: Nov 19 2009 10:22PM Matching: pharmaceuticals
- [Webcast Alert: Isis Pharmaceuticals Announces Its R&D Webcast Presentation](#)
Wichita Business Journal: Nov 19 2009 12:59PM Matching: pharmaceuticals

GelTex Pharmaceuticals Incorporated Patents:



- 5917007- [Process for removing bile salts from a patient and alkylated compositions therefor](#)
- 6083497- [Method for treating hypercholesterolemia with unsubstituted polydiallylamine polymers](#)
- 6129910- [Water-insoluble noncrosslinked bile acid sequestrants](#)
- 6177478- [Method for reducing oxalate](#)
- 6187762- [Polyvalent polymers for the treatment of rotavirus infection](#)
- 6190649- [Polyether-based bile acid sequestrants](#)
- 6203785- [Poly\(diallylamine\)-based bile acid sequestrants](#)
- 6225355- [Process for removing bile salts from a patient and alkylated compositions therefor](#)
- 6235720- [Acid-functionalized saccharide polymers](#)
- 6248318- [Method for treating hypercholesterolemia with unsubstituted polydiallylamine polymers](#)
- 6264937- [Fat-binding polymers](#)
- 6083495- [Method of making phosphate-binding polymers for oral administration](#)
- 6066678- [Process for removing bile salts from a patient and alkylated compositions therefor](#)
- 6060517- [Process for removing bile salts from a patient and compositions therefor](#)

- 5919832- [Amine polymer sequestrant and method of cholesterol depletion](#)
- 5925379- [Interpenetrating polymer networks for sequestration of bile acids](#)
- 5929184- [Hydrophilic nonamine-containing and amine-containing copolymers and their use as bile acid sequestrants](#)
- 5939537- [Acid-functionalized saccharide monomers](#)
- 5969090- [Hydrophobic sequestrant for cholesterol depletion](#)
- 5981693- [Process for removing bile salts from a patient and alkylated compositions therefor](#)
- 5985938- [Method for reducing oxalate](#)
- 6007803- [Ionic polymers as toxin binding agents](#)
- 6034129- [Ionic polymers as anti-infective agents](#)
- 6060235- [Antiviral polymers comprising acid functional groups and hydrophobic groups](#)
- 6264938- [Combination therapy for treating hypercholesterolemia](#)
- 6267952- [Lipase inhibiting polymers](#)
- 6482402- [Antimicrobial compositions and methods](#)
- 6509013- [Method of making phosphate-binding polymers for oral administration](#)
- 6517825- [Polyether-based bile acid sequestrants](#)
- 6517826- [Anionic polymers as toxin binders and antibacterial agents](#)
- 6517827- [Anionic polymers as toxin binders and antibacterial agent](#)
- 6558657- [Lipase inhibiting polymers](#)
- 6565895- [Bismuth compounds for the treatment and prevention of mucositis](#)
- 6566407- [Method for reducing oxalate](#)
- 6572850- [Lipase inhibiting polymers](#)
- 6593366- [Ionic polymers as anti-infective agents](#)
- 6433026- [Process for removing bile salts from a patient and alkylated compositions therefor](#)
- 6423754- [Method for treating hypercholesterolemia with polyallylamine polymers](#)
- 6419914- [Anionic polymers as toxin binders](#)
- 6268126- [Antiviral polymers comprising acid functional groups and hydrophobic groups](#)
- 6270755- [Anionic polymers as toxin binders](#)
- 6271264- [Polymers containing spirobicyclic ammonium moieties as bile acid sequestrants](#)
- 6290946- [Anionic polymers as toxin binders and antibacterial agents](#)
- 6290947- [Ionic polymers as toxin-binding agents](#)
- 6294163- [Polymers containing guanidinium groups as bile acid sequestrants](#)
- 6299868- [Fat-binding polymers](#)
- 6352692- [Lipase inhibiting polymers](#)
- 6365186- [Combination therapy for treating hypercholesterolemia](#)
- 6395777- [Ionic polymers as anti-infective agents](#)
- 6646157- [Method for making HBED](#)

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search

- engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

